The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis
Open accessAbstract
Background and Aims Studies are needed to determine the long-term effects of bariatric surgery for patients with nonalcoholic steatohepatitis (NASH). We evaluated sequential liver samples, collected the time of bariatric surgery and 1 and 5 years later, to assess the long-term effects of bariatric surgery in patients with NASH. Methods We performed a prospective study of 180 severely obese patients with biopsy-proven NASH, defined by the NASH clinical research network histologic scores. The patients underwent bariatric surgery at a single center in France and were followed for 5 years. We obtained liver samples from 125 of 169 patients (76%) having reached 1 year and 64 of 94 patients (68%) having reached 5 years after surgery. The primary endpoint was the resolution of NASH without worsening of fibrosis at 5 years. Secondary end points were improvement in fibrosis (reduction of ≥1 stage) at 5 years and regression of fibrosis and NASH at 1 and 5 years. Results At 5 years after bariatric surgery, NASH was resolved, without worsening fibrosis, in samples from 84% of patients (n = 64; 95% confidence interval, 73.1%-92.2%). Fibrosis decreased, compared with baseline, in samples from 70.2% of patients (95% CI, 56.6%-81.6%). Fibrosis disappeared from samples from 56% of all patients (95% CI, 42.4%-69.3%) and from samples from 45.5% of patients with baseline bridging fibrosis. Persistence of NASH was associated with no decrease in fibrosis and less weight loss (reduction in body mass index of 6.3 ± 4.1 kg/m 2 in patients with persistent NASH vs reduction of 13.4 ± 7.4 kg/m 2 ; P = .017 with resolution of NASH). Resolution of NASH was observed at 1 year after bariatric surgery in biopsies from 84% of patients, with no significant recurrence between 1 and 5 years ( P = .17). Fibrosis began to decrease by 1 year after surgery and continued to decrease until 5 years ( P < .001). Conclusions In a long-term follow-up of patients with NASH who underwent bariatric surgery, we observed resolution of NASH in liver samples from 84% of patients 5 years later. The reduction of fibrosis is progressive, beginning during the first year and continuing through 5 years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In an observational study, MASH was resolved in 84% of 180 individuals with class 2 obesity and MASH 5 years after Roux-en-Y gastric bypass (66%), sleeve gastrectomy (12%) or gastric banding (22%).”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [443]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Pioglitazone therapy, GLP-1 RA therapy, and metabolic surgery have all been shown to reduce NASH activity; pioglitazone therapy and metabolic surgery may also improve hepatic fi brosis (188,292 -298).”
The cited source says what the claim attributes to it.
In the citing paper
“One of the most promising developments in the field is the growing consensus that liver fibrosis can be a reversible process under certain conditions, particularly if the underlying cause of injury is removed (84–86).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [85]
The cited source says what the claim attributes to it.
In the citing paper
“Procedures like Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG) are associated with significant metabolic improvements and reductions in NAFLD severity [13,14,15], including reductions in liver fat, liver enzymes, and fibrosis [16,17,18].”
From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [16]
In the citing paper
“The reduction of fibrosis is progressive, beginning during the first year and continuing through 5 years [4,127].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [127]
In the citing paper
“In a long-term follow-up study of patients with MASH who underwent bariatric surgery, the resolution of MASH in liver samples was observed from 84% of patients 5 years later.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [127]
In the citing paper
“Weight loss either through lifestyle intervention68 or bariatric surgery (Roux-en-Y gastric bypass or sleeve gastrectomy)69,70 improves the lipid profile by reducing total TAGs, and increasing PC, PE and HDL concentrations.125”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [70]
In the citing paper
“Nevertheless, these interventions suggest that, like HCV and HBV, MASH fibrosis is reversible in non-cirrhotic liver, but unlike in HCV and HBV there is no evidence yet that cirrhosis in MASH is reversible (259).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [259]
In the citing paper
“Wound healing in the liver is dynamic and reversible,105 with ample evidence of fibrosis regression after effective treatment of viral hepatitis, and even following bariatric surgery in patients with NASH.106”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [106]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Bariatric Surgery: A Systematic Review and Meta-analysis
Buchwald, H., Avidor, Y., Braunwald, E., Jensen, M. D., Pories, W., Fahrbach, K., & Schoelles, K. (2004) · JAMA · doi:10.1001/jama.292.14.1724 · Cited by 6,800
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Chalasani, N., Younossi, Z. M., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. J., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,854
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes
Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Aminian, A., Brethauer, S. A., Navaneethan, S. D., Singh, R. P., Pothier, C. E., Nissen, S. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1600869 · Cited by 2,934
Long-term mortality after gastric bypass surgery
Adams, T. D., Gress, R. E., Smith, S. C., Halverson, R. C., Simper, S. C., Rosamond, W. D., LaMonte, M. J., Stroup, A. M., & Hunt, S. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066603 · Cited by 2,572
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 620
Baseline Presence of NAFLD Predicts Weight Loss after Gastric Bypass Surgery for Morbid Obesity
Rheinwalt, K. P., Drebber, U., Schierwagen, R., Klein, S., Neumann, U. P., Ulmer, T. F., Plamper, A., Kroh, A., Schipper, S., Odenthal, M., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113430 · Cited by 22
Thabut, D., Dasari, B. V. M., Allaire, M., Berzigotti, A., Blasi, A., Line, P., Mandorfer, M., Mazzafero, V., & Hernández–Gea, V. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.04.008 · Cited by 24
Dissecting the mechanisms of MASLD fibrosis in the era of single-cell and spatial omics
Colella, F., Henderson, N. C., & Ramachandran, P. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186421 · Cited by 25
“In MASLD, detailed phenotyping of patients following bariatric surgery demonstrated that 45.5% of patients with advanced fibrosis (F3–F4) at baseline showed complete resolution after 5 years (166).”
InfluentialAnti-diabetic drugs and NASH: from current options to promising perspectives
Smati, S., Canivet, C. M., Boursier, J., & Cariou, B. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1951701 · Cited by 21
Ren, M., Zhou, X., Zhang, Y., Mo, F., Yang, J., Yu, M., & Ji, F. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.931519 · Cited by 21
“Recent studies have shown the benefit of bariatric surgery on the histologic and serologic features of NAFLD/NASH (7).”
BackgroundInfluentialWang, G., Zhang, X., Wang, C., & Guan, Y. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i1.75 · Cited by 21
Summary of a consensus conference on heart-liver transplantation
KOBASHIGAWA, J. A., VanWagner, L. B., Hall, S. A., Emamaullee, J. A., Entwistle, J. W., Ganger, D. R., Gebel, H. M., Jeevanandam, V., Kaldas, F. M., Kılıç, A., et al. (2023) · American Journal of Transplantation · doi:10.1016/j.ajt.2023.12.002 · Cited by 21
Associazione Italiana per lo Studio del Fegato (AISF), S. I. D. D. (. A. S. I. D. (. (2021) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-021-01287-1 · Cited by 22
Caussy, C., Cusi, K. J., Rosenstock, J., Bugianesi, E., Thomas, M. K., Tang, Y., Mather, K. J., Loomba, R., Sanyal, A. J., & Hartman, M. L. (2025) · Diabetes Care · doi:10.2337/dc25-1306 · Cited by 22
Mazzini, G. S., Augustin, T., Noria, S. F., Romero‐Marrero, C., Li, N., Hameed, B., Eisenberg, D., Azagury, D. E., & Ikramuddin, S. (2021) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2021.11.015 · Cited by 20
What’s new in non-alcoholic fatty liver disease?
Spiers, J., Brindley, J. H., Li, W., & Alazawi, W. (2022) · Frontline Gastroenterology · doi:10.1136/flgastro-2022-102122 · Cited by 22
Jia, X., Song, E., Liu, Y., Chen, J., Wan, P., Hu, Y., Ye, D., Chakrabarti, S., Mahajan, H., George, J., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101257 · Cited by 20
“39 Our longitudinal study observed marked decreases in circulating sCDCP1 after bariatric surgery, independent of weight loss.”
BackgroundTransforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists
Jensen, E., Israelsen, M. E., & Krag, A. A. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000561 · Cited by 24
Sarcopenia in MASLD—Eat to Beat Steatosis, Move to Prove Strength
Crișan, D., Avram, L., Morariu-Barb, A. M., Grapa, C. M., Hirişcău, E. I., Crăciun, R., Donca, V., & Nemeș, A. (2025) · Nutrients · doi:10.3390/nu17010178 · Cited by 21
“…studies have shown that BS leads to an important reduction in major adverse liver-related outcomes [104], long-term resolution of MASH, and fibrosis regression [105,106], regardless of the surgical technique [107], being significantly more effective compared to other therapeutic approaches [108].”
Manzano-Núñez, R., Rivera‐Esteban, J., Comas, M., Angel, M., Flores, V., Bañares, J., Ciudin, A., Vilallonga, R., & Pericàs, J. M. (2022) · Obesity Surgery · doi:10.1007/s11695-022-06362-9 · Cited by 19
“This finding further supports what is already known [34, 35]: BS is associated with improvements in steatosis, steatohepatitis, and fibrosis in individuals with obesity and fatty liver disease.”
ResultMantziari, S., Abboretti, F., Favre, L., Thomopoulos, T., Barigou, M., Demartines, N., & Suter, M. (2022) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2022.12.032 · Cited by 20
SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review
Xu, R., Lian, D., Xie, Y., Chen, Z., Wang, Y., Mu, L., Wang, Y., & Zhang, B. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2807134 · Cited by 22
“Another 5-year follow-up of NASH patients who underwent bariatric surgery, showed results that were also consistent [88].”
ResultManagement of NAFLD patients with advanced fibrosis
Maya‐Miles, D., Ampuero, J., Gallego‐Durán, R., D’Ingianna, P., & Romero‐Gómez, M. (2021) · Liver International · doi:10.1111/liv.14847 · Cited by 19
Adinolfi, L. E., Marrone, A., Rinaldi, L., Nevola, R., Izzi, A., & Sasso, F. C. (2025) · Exploration of Medicine · doi:10.37349/emed.2025.1001281 · Cited by 18
Larson, E. L., Ellias, S. D., Blezek, D. J., Klug, J., Hartman, R. P., Francisco‐Ziller, N., Bamlet, H., Mao, S. A., Perry, D. K., Nimma, I. R., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.02.030 · Cited by 18
Research Priorities for Precision Medicine in NAFLD
Iruzubieta, P., Bataller, R. A., Arias, M., Arrese, M. A., Calleja, J. L., Castro‐Narro, G., Cusi, K. J., Dillon, J. F., Martínez‐Chantar, M. L., Mateo, M., et al. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.016 · Cited by 18
Koutoukidis, D. A., Mózes, F. E., Jebb, S. A., Tomlinson, J., Pavlides, M., Saffioti, F., Huntriss, R., Aveyard, P. N., & Cobbold, J. (2023) · Obesity · doi:10.1002/oby.23793 · Cited by 19
“This is based on evidence that NASH or fibrosis may worsen after bariatric surgery in 10% of patients [15], that alanine aminotransferase (ALT) increases transiently during TDR [16], and that fibrosis may develop in patients losing at least 1.”
BackgroundXie, C., Alkhouri, N., & Elfeki, M. A. (2024) · World Journal of Hepatology · doi:10.4254/wjh.v16.i5.731 · Cited by 22
Rouillard, N. A., Barnett, S. D., Zhang, X., Kam, L. Y., Manikat, R., Cheung, R. C., & Nguyen, M. H. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0564 · Cited by 20
Zhu, N., Li, Y., Lin, Y., Cui, X., & Li, X. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2024.1491858 · Cited by 17
Non-Alcoholic Fatty Liver Disease (NAFLD) Management in the Community
Park, Y. B., Ko, K. S., & Rhee, B. D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062758 · Cited by 19
Sabench, F., Bertran, L., Vives, M., París, M., Aguilar, C., Martínez, S., Binetti, J., Real, M., Alibalic, A., Richart, C., et al. (2022) · Obesity Surgery · doi:10.1007/s11695-022-06175-w · Cited by 17
Ren, M., Zhou, X., Yu, M., Cao, Y., Xu, C., Yu, C., & Ji, F. (2023) · Digestive Endoscopy · doi:10.1111/den.14409 · Cited by 17
Ding, Y., Deng, Q., Yang, M., Niu, H., Wang, Z., & Xia, S. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s431251 · Cited by 23
Liu, Y., Qin, X., Chen, T., Chen, M., Wu, L., & He, B. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1344924 · Cited by 18
Herrington, G., Peterson, J., Cheng, L., Allington, B. M., Jensen, R. D., Healy, H. S., & Correia, M. (2022) · Obesity Science & Practice · doi:10.1002/osp4.589 · Cited by 16
Nonalcoholic fatty liver disease and diabetes
Bellini, M. I., Urciuoli, I., Gaudio, G. D., Polti, G., Iannetti, G., Gangitano, E., Lori, E., Lubrano, C., Cantisani, V., Sorrenti, S., et al. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i9.668 · Cited by 18
Tan, H. C., Shumbayawonda, E., Beyer, C., Cheng, L. T., Low, A. S.-C., Lim, C. H., Eng, A. K. H., Chan, W. H., Lee, P. C., Tay, M. F., et al. (2023) · International Journal of Biomedical Imaging · doi:10.1155/2023/4228321 · Cited by 17
Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH
Finan, B., Parlee, S. D., & Yang, B. S. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101153 · Cited by 16
“It has been shown that that sustained weight loss of 10% is associated with a reduction in liver fibrosis [19], bariatric surgery provides long-term resolution of NASH and fibrosis regression [29], and meta-analysis of the NASH clinical trials shows an association between weight loss and biomarkers indicative of impro…”
Backgroundvan Dijk, A., Schattenberg, J. M., Holleboom, A. G., & Tushuizen, M. E. (2021) · United European Gastroenterology Journal · doi:10.1002/ueg2.12150 · Cited by 16
“18,25,34 - 907 systematic review of Lee et al. showed that bariatric surgery in severely obese patients leads to a complete resolution of liver biopsy proven NAFLD fibrosis in around 40% of the patients.”
Tissue regeneration: Unraveling strategies for resolving pathological fibrosis
Li, J., Wang, S., Yuan, J., Mao, X., Wang, X., Zhang, L., Dong, Q., Chen, Z., Wang, Y., & Tang, N. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.10.002 · Cited by 19
Martínez‐Montoro, J. I., Kuchay, M. S., Román, A. B., Martínez‐Sánchez, M. A., Frutos, M. D., Fernández‐García, J. C., & Ramos‐Molina, B. (2021) · Obesity Reviews · doi:10.1111/obr.13367 · Cited by 16
“Lassailly et al.(27) Prospective cohort 180 RYGB/SG/GB (60 months) Biopsy 84% resolution of NASH without worsening fibrosis; 70% fibrosis improvement; 56% fibrosis resolution”
BackgroundNAFLD and NASH: The Metabolically Diseased Liver
Armandi, A., & Schattenberg, J. M. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_561 · Cited by 16
Ciardullo, S., Pizzi, M., Pizzi, P., Oltolini, A., Muraca, E., & Perseghin, G. (2022) · Obesity Surgery · doi:10.1007/s11695-021-05885-x · Cited by 15
“In this context, bariatric surgery, which is the most effective measure to achieve profound and sustained weight loss, represents a valuable tool for the treatment of MAFLD as well, with large reductions in inflammation and fibrosis following different bariatric procedures [8, 9].”
BackgroundInfluentialPark, A., Choi, S. J., Park, S., Kim, S. M., Lee, H., Joo, M., Kim, K. K., Kim, D., Chung, D. H., Im, J.-B., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095035 · Cited by 15
“It was reported that a mean BMI reduction of 12 kg/m2 or more after bariatric surgery was more likely to be associated with the resolution of NASH without progression of fibrosis [2].”
BackgroundPais, R., Cariou, B., Noureddin, M., Francque, S., Schattenberg, J. M., Abdelmalek, M. F., Lalazar, G., Varma, S., Dietrich, J., Miller, V., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.014 · Cited by 15
Brennan, P., Zelber‐Sagi, S., Allen, A. M., Dillon, J. F., & Lazarus, J. V. (2023) · Gut · doi:10.1136/gutjnl-2023-330771 · Cited by 17
“…literature supporting bariatric-metabolic surgery, when compared with current best-practice approaches, in reducing all-cause mortality from major adverse cardiovascular events (MACE) and liver-related outcomes, 26 27 as a result of a substantial weight loss of ~14%–25% that is sustained long-term.”
ResultMendoza, Y. P., Tsouka, S., Semmler, G., Seubnooch, P., Freiburghaus, K., Mandorfer, M., Bosch, J., Masoodi, M., & Berzigotti, A. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.028 · Cited by 16
Billeter, A. T., Scheurlen, K. M., Israel, B., Straub, B. K., Schirmacher, P., Kopf, S., Nawroth, P. P., & Müller-Stich, B. P. (2022) · Annals of Surgery · doi:10.1097/sla.0000000000005631 · Cited by 15
S2k-Leitlinie Klinische Ernährung in der Hepatologie
Plauth, M., Bechmann, L. P., Grajecki, D., Gundling, F., Kramer, L., Kremer, A. E., Rau, M., Schneider, A., Tacke, F., & van Thiel, I. (2024) · Aktuelle Ernährungsmedizin · doi:10.1055/a-2338-1144 · Cited by 14
Kawanaka, M., Kamada, Y., Takahashi, K., Iwaki, M., Nishino, K., Zhao, W., Seko, Y., Yoneda, M., Kubotsu, Y., Fujii, H., et al. (2024) · Gastro Hep Advances · doi:10.1016/j.gastha.2024.08.008 · Cited by 14
Advances in the Epidemiology, Diagnosis, and Management of Pediatric Fatty Liver Disease
Suri, A., Song, E., van Nispen, J., Voigt, M., Armstrong, A. T., Murali, V., & Jain, A. K. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.01.006 · Cited by 14
Yang, M. J., Khoukaz, L., Qi, X., Kimchi, E. T., Staveley-O’Carroll, K. F., & Li, G. (2021) · Biomedicines · doi:10.3390/biomedicines9121893 · Cited by 17
Combination strategies for pharmacologic treatment of non-alcoholic steatohepatitis
Suri, J. S., Borja, S., & Lim, J. K. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i35.5129 · Cited by 14
Bariatric surgery for diabetic comorbidities: A focus on hepatic, cardiac and renal fibrosis
Ding, H., Zhang, Y., Ma, X., Zhang, Z., Xu, Q., Liu, C., Li, B., Dong, S., Li, L., Zhu, J., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1016635 · Cited by 16
“Fibrosis began to decrease 1 year after surgery and continued to decrease within 5 years (Lassailly et al., 2020).”
BackgroundRoehlen, N., Laubner, K., Nicolaus, L., Schwacha, H., Bettinger, D., Krebs, A., Thimme, R., & Seufert, J. (2022) · Nutrition · doi:10.1016/j.nut.2022.111806 · Cited by 17
Obesity and climate change: co-crises with common solutions
Behrens, P., Champagne, C. M., Halford, J. C. G., Moodie, M., Proietto, J., Rutter, G. A., Samaras, K., & Holly, J. M. P. (2025) · Frontiers in Science · doi:10.3389/fsci.2025.1613595 · Cited by 13
Grocic, M., Nguyen, M., & Sanyal, A. J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70662 · Cited by 16
“In another study of patients with class 2 obesity, MASH resolution up to 5 years post-procedure was noted in 66% of patients who underwent RYGB, 12% who underwent sleeve gastrectomy, and 22% who underwent gastric banding [95].”
Therapeutic developments in metabolic dysfunction-associated fatty liver disease
Shi, Y., & Fan, J. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002091 · Cited by 14
“The fibrosis improvement also continued until 5 years after bariatric surgery.([35]) As for MAFLD patients with advanced fibrosis ormorbid obesity, bariatric surgerywould bemore cost-effective in improving quality-adjusted life-years, compared to those without fibrosis or morbid obesity.”
BackgroundLajeunesse‐Trempe, F., Okrój, D., Oštarijaš, E., Ramalho, A., Tremblay, È.-J., Llewellyn, D. J., Harlow, C. F., Chandhyoke, N., Chew, N., Vincent, R. P., et al. (2024) · Obesity Reviews · doi:10.1111/obr.13759 · Cited by 14
“11 – 14 Such metabolic improvements need to be considered when assessing patient medications pre-and post-operatively.”
Billmann, F. G., Shishtawi, S. E., Bruckner, T., ElSheikh, M., Müller-Stich, B. P., & Billeter, A. T. (2021) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-21-71 · Cited by 12
“Moreover, bariatric procedures not only decrease the likelihood of progression to hepatic decompensation but may also have the potential to reverse existing liver damage (13).”
Obesity and Nonalcoholic Fatty Liver Disease
Chaney, A. J. (2021) · Nursing Clinics of North America · doi:10.1016/j.cnur.2021.07.009 · Cited by 14
A review on the beneficial effects of bariatric surgery in the management of obesity
Wahab, R. A., & le Roux, C. W. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2110865 · Cited by 19
“accompanied by biopsy-proven NASH, resolution of the disease was observed in 84% of patients 5 years following surgery, with a progressive reduction in liver fibrosis from year 1 to 5 postoperatively [66].”
Sleeve gastrectomy causes weight‐loss independent improvements in hepatic steatosis
McGlone, E. R., Siebert, M., Dore, M. H., Hope, D. C. D., Davies, I., Owen, B. M., Khoo, B. C. E., Goldin, R. D., Carling, D., Bloom, S. R., et al. (2023) · Liver International · doi:10.1111/liv.15614 · Cited by 12
Alonso‐Peña, M., Barrio, M. D., Peleteiro‐Vigil, A., Jiménez-González, C., Santos‐Laso, Á., Arias, M., Iruzubieta, P., & Crespo, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310718 · Cited by 16
Azulai, S., Grinbaum, R., Beglaibter, N., Eldar, S. M., Rubin, M., Ben-Haroush Schyr, R., Romano-Zelekha, O., & Ben-Zvi, D. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10051144 · Cited by 13
“RYGB was shown to be superior to gastric banding, in long-term histological studies in improving NASH [3,8] and OAGB shows great promise in improving NASH in histological studies [17].”
BackgroundResultThe role of bariatric surgery in the management of nonalcoholic steatohepatitis
Seymour, K. A., & Abdelmalek, M. F. (2021) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000721 · Cited by 13
Semaglutide or Placebo for Nonalcoholic Steatohepatitis
Newsome, P. N., Sejling, A.-S., & Sanyal, A. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2106921 · Cited by 13
Tasabehji, D., Saleh, S., & Mokadem, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14124012 · Cited by 14
Bariatric surgery in liver cirrhosis
Mehdorn, A., Moulla, Y., Mehdorn, M., Dietrich, A., Schönfels, W. V., Becker, T., Braun, F., Beckmann, J. H., & Linecker, M. (2022) · Frontiers in Surgery · doi:10.3389/fsurg.2022.986297 · Cited by 12
“reported on 5-yearbiopsy-proven remission of NASH and hepatic fibrosis in 180 patients after BS for severe obesity (32).”
BackgroundRole of the Gut Microbiome in Metabolic Dysfunction-Associated Steatotic Liver Disease
Maher, S., Rajapakse, J., El-Omar, E. M., & Zekry, A. (2024) · Seminars in Liver Disease · doi:10.1055/a-2438-4383 · Cited by 14
“156,157 In this context, studies have identi fi ed gut microbial changes associated with RYGB and sleeve gastrectomy, but not vertical banded gastroplasty.”
Sabench, F., Rusu, E. C., Clavero-Mestres, H., Arredondo-Prats, V., Veciana-Molins, M., Muñiz-Piera, S., Vives, M., Aguilar, C., Bartra, È., París, M., et al. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07585-8 · Cited by 12
“MASLD represents a clinical syndrome caused by excessive fat deposition in hepatocytes and includes histopathological entities ranging from simple steatosis (SS) and metabolic dysfunction associated steatohepatitis (MASH) to its advanced stages, including hepatic fibrosis and cirrhosis [4].”
Singal, A. K., Pannerselvam, D., Arab, J. P., Im, G. Y., & Kuo, Y. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003259 · Cited by 12
Bernhard, J., Galli, L., Speidl, W. S., & Krychtiuk, K. A. (2025) · Current Cardiology Reports · doi:10.1007/s11886-024-02185-5 · Cited by 18
“Despite the lack of prospective randomized studies in the context of CVD prevention and MASLD, retrospective studies and meta-analyses have suggested beneficial effects associated with bariatric surgery in both indications [90–92].”
Liu, C., & Liu, C. (2025) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes25028 · Cited by 12
“22,23”
Medina, S. P., Kim, R. G., Magee, C., Stapper, N., & Khalili, M. (2023) · Obesity Science & Practice · doi:10.1002/osp4.688 · Cited by 12
López, A. P. L., Tuli, S., Lauze, M., Becetti, I., Pedreira, C. C., Huber, F. A., Ömeroğlu, E., Singhal, V., Misra, M., & Bredella, M. A. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad390 · Cited by 13
Raverdy, V., Chatelain, E., Lassailly, G., Caiazzo, R. J., Vandel, J., Verkindt, H., Marciniak, C., Legendre, B. L., Bauvin, P., Daoud, N. O., et al. (2023) · Obesity · doi:10.1002/oby.23904 · Cited by 14
“As previously described [23], the diagnosis of NASH was defined by the presence and pattern of specific histological abnormalities on liver biopsy using the Brunt scoring system for NASH [26].”
MethodSelf-citationEffects of anti-diabetic treatments in type 2 diabetes and fatty liver disease
Lamos, E. M., Kristan, M. M., Siamashvili, M., & Davis, S. N. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1917374 · Cited by 12
Billeter, A. T., Reiners, B., Seide, S. E., Probst, P., Kalkum, E., Rupp, C., & Müller-Stich, B. P. (2022) · Hepatobiliary Surgery and Nutrition · doi:10.21037/hbsn-21-5 · Cited by 12
“Furthermore, long-term follow-up from the Lille-bariatric cohort with repeat liver biopsy five years after bariatric surgery in patients with NASH also revealed a sustained NASH-resolution and even better improvement of fibrosis over time (23).”
BackgroundSuppressing MASH fibrotic progression by blocking succinate-GPR91 signaling in HSCs
Xie, L., Chen, H., Zhang, L., Yang, Y., Zhou, Y., Ma, Y., Liu, C., Wang, Y.-L., Zhu, Q., Yan, Y.-J., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001405 · Cited by 11
Chauhan, K., Khan, A., Chowdhury, S., Ross, H. M., Parra, N. S., & Halegoua-DeMarzio, D. L. (2022) · Livers · doi:10.3390/livers2020006 · Cited by 11
Ciccarelli, G., Giuseppe, G. D., Cinti, F., Moffa, S., Mezza, T., & Giaccari, A. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3668 · Cited by 11
Papaetis, G. S., Picolos, M. K., & Sacharidou, A. (2025) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/202298 · Cited by 12
The Liver in Diabetes and Metabolic Syndrome
Mahmoud, M. C., & Abdelmalek, M. F. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.04.003 · Cited by 14
Hussein, A., Awashra, A., Rajab, I. M., Bdair, M., Hamdan, D., Nouri, A., Khatib, E., Khatib, G., & Latt, N. L. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70075 · Cited by 11
“Supporting this, Lassailly et al. [16], in their study, showed that long-term follow-up research indicates that up to 84% of patients achieve NASH resolution within five years after surgery.”
Semaglutide in MASLD Patients: Improved Survival and Liver Outcomes
Suki, M., Amer, J., Milgrom, Y., Massarwa, M., Hazou, W., Tiram, Y., Perzon, O., Sharif, Y., Sackran, J., Alon, R., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18071075 · Cited by 11
“…is comparable to or better than results reported with other pharmacological interventions such as cenicriviroc (which failed to show efficacy on fibrosis in phase 3 despite phase 2b promise [25]) or obeticholic acid [8] and potentially complementary to the effects seen with bariatric surgery [26].”
Rinella, M. E., Cryer, D. R. H., Articolo, A., Fisher, T., Schneider, J. L., & Nadolsky, K. Z. (2022) · BMC Gastroenterology · doi:10.1186/s12876-022-02410-x · Cited by 11
“Similarly, weight loss achieved with anti-obesity medications [27], lifestyle changes [28], or bariatric surgery [29] can have a positive impact on NASH.”
BackgroundSandvik, E. C. S., Aasarød, K. M., Johnsen, G., Hoff, D. A. L., Kulseng, B. E., Hyldmo, Å. A., Græslie, H., Nymo, S., Sandvik, J., & Fossmark, R. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164910 · Cited by 11
“The diagnosis represents a range of different stages of chronic liver disease, including non-alcoholic steatohepatitis (NASH), a more severe form with a significant risk of cirrhosis development.”
BackgroundInfluentialAdvances in obesity pharmacotherapy; learning from metabolic surgery and beyond
Tsilingiris, D., & Kokkinos, A. D. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155741 · Cited by 13
Martínez‐Montoro, J. I., Arranz‐Salas, I., Gutiérrez‐Repiso, C., García, A. M. S., Ocaña-Wilhelmi, L., Pinazo-Bandera, J. M., Fernández‐García, D., Muñoz‐Garach, A., Morales-García, D. J., García‐Cortés, M., et al. (2024) · Nutrients · doi:10.3390/nu16223857 · Cited by 10
“…have shown that the persistence of MASH after BS might be associated with less weight loss following the intervention, and changes in liver histology may affect weight loss [32], this could be an important point to consider, which was not evaluated in our study and could have impacted our results.”
Incretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders
Farrugia, M. A., Pini, E., Tran, A., Chevalier, N., Anty, R., & Gual, P. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00646-8 · Cited by 11
Evaluating future risk of NAFLD in adolescents: a prediction and decision curve analysis
Abeysekera, K. W. M., Orr, J. G., Gordon, F. H., Howe, L. D., Hamilton-Shield, J. P., Heron, J., & Hickman, M. (2022) · BMC Gastroenterology · doi:10.1186/s12876-022-02401-y · Cited by 12
Kreve, F., Callejas, G. H., Jimenez, L. S., Marques, R. A., Chaim, F. D. M., Utrini, M. P., Gestic, M. A., RAMOS, A. C., Chaim, E. A., & Cazzo, E. (2022) · Sao Paulo Medical Journal · doi:10.1590/1516-3180.2021.0828.07012022 · Cited by 10
Epigenetic memory of environmental exposures as a mediator of liver disease
Hlady, R. A., & Robertson, K. D. (2023) · Hepatology · doi:10.1097/hep.0000000000000414 · Cited by 10
Nadolsky, K. Z., Cryer, D. R. H., Articolo, A., Fisher, T., Schneider, J. L., & Rinella, M. E. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2211349 · Cited by 12
“…of hepatologists and gastroenterologists [17]. studies show that lifestyle, drug, or surgically-induced weight loss can improve Nash [11,31–33]. similarly, effectively managing t2DM can lead to liver fibrosis improvement. a study involving serial liver biopsies of Japanese patients with…”
BackgroundHu, R., Wu, B., Wang, C., Wu, Z., Zhang, X., Chen, X., Lu, G., & Yuan, K. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001078 · Cited by 10
Navarro‐Masip, È., Petit, N. M., Zorzano-Martínez, M., Salinas‐Roca, B., Sánchez, E., López‐Cano, C., Herrerías, F., de la Fuente, M. C., Santamaría, M., León, J., et al. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07071-1 · Cited by 10
“…obesity and biopsy-proven NASH and found that NASH resolution without worsening fibrosis occurred in 84% of cases at 5 years post-bariatric surgery, thus reinforcing the reliability of this non-invasive technique for MAFLD diagnoses and encouraging the avoidance of more invasive approaches [35].”
Lim, W. H., Lin, S. Y., Ng, C. H., Tan, D. J. H., Xiao, J., Yong, J. N., Tay, P. W. L., Syn, N. L. X., Chin, Y. H., Chan, K. E., et al. (2022) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-21-520 · Cited by 10
“, RYGB, SG, adjustable gastric banding (AGB), intragastric balloon (IGB), DJBL, vertical banded gastroplasty] were excluded from the analysis (23-25).”
BackgroundImprovement in nonalcoholic fatty liver disease through bariatric surgery
Truong, E., & Noureddin, M. (2022) · Clinical Liver Disease · doi:10.1002/cld.1229 · Cited by 10
Zou, X., & Brigstock, D. R. (2024) · Biomedicines · doi:10.3390/biomedicines12122848 · Cited by 10
Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms
Møller, S., Kimer, N., Kronborg, T. M., Grandt, J., Hove, J. D., Barloese, M. C. J., & Gluud, L. L. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1725022 · Cited by 10
Emerging concepts in the detection of liver fibrosis in non-alcoholic fatty liver disease
Armandi, A., Michel, M. S., Gjini, K., Emrich, T., Bugianesi, E., & Schattenberg, J. M. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2242779 · Cited by 9
“strated not only that NASH is reversible, but that this regression is accompanied by fibrosis improvement [35].”
BackgroundJuárez-Hernández, E., Velázquez-Alemán, A. P., Castro‐Narro, G., Uribe, M., & López-Méndez, I. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1026444 · Cited by 9
“Regarding liver disease, BS has demonstrated resolution of NASH and progressive reduction of fibrosis in long term follow-up (15); moreover, and compared with non-surgical treatments, BS has been associated with lower cardiovascular risk, which is the most common cause of death in NAFLD patients (6, 16).”
BackgroundIannelli, A., Bulsei, J., Debs, T., Tran, A., Lazzati, A., Gugenheim, J., Anty, R., Petrucciani, N., & Fontas, É. (2021) · Obesity Surgery · doi:10.1007/s11695-021-05684-4 · Cited by 8
“While BS has been shown to have a protective effect against the onset and/or the progression of non-alcoholic steatohepatitis (NASH) and liver cirrhosis [4], patients with a previous history of BS may become candidate to liver transplantation (LT) because of acute or chronic liver failure or development of primary liv…”
Background
Metadata
- Authors
- Lassailly, G., Caiazzo, R., Ntandja-Wandji, L.-C., Gnemmi, V., Baud, G., Verkindt, H., Ningarhari, M., Louvet, A., Leteurtre, E., Raverdy, V., Dharancy, S., Pattou, F., & Mathurin, P.
- Affiliations
- Inserm (FR)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Pattou, François
- Mathurin, Philippe
- ORCID
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 159
- Issue
- 4
- Pages
- 1290-1301.e5
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W3034346518
- Cited by
- 622
- References
- 27
- Citations by year
- 2026: 93 · 2025: 105 · 2024: 109 · 2023: 106 · 2022: 108 · 2021: 89 · 2020: 11
- FWCI
- 56.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Gastroenterology (acceptedVersion, other-oa)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by-nc)
- HAL (submittedVersion)
- LillOA (Université de Lille (University Of Lille)) (submittedVersion, other-oa)
- Funders
- European Regional Development Fund
- Agence Nationale de la Recherche (ANR-10-LABX-46, ANR-16-RHUS-0006)
- Ministère des Affaires Sociales et de la Santé
- European Commission
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Surgery › Organ Transplantation Techniques and Outcomes
- Keywords
- bariatric surgery, nonalcoholic steatohepatitis, liver fibrosis regression, obesity, long-term outcomes, weight loss, NASH resolution, liver biopsy histology, bridging fibrosis, metabolic surgery, liver cancer risk, liver transplantation risk
- MeSH terms
- Adult, Biopsy, Female, Follow-Up Studies, France, Humans, Liver, Liver Cirrhosis, Male, Middle Aged, Obesity, Morbid, Prospective Studies, Remission Induction, Time Factors, Weight Loss, Treatment Outcome, Bariatric Surgery, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
